Antibiotic dosing in critically ill patients with acute kidney injury

被引:76
作者
Eyler, Rachel F. [1 ]
Mueller, Bruce A. [1 ]
机构
[1] Univ Michigan, Coll Pharm, Dept Clin Social & Administrat Sci, Ann Arbor, MI 48109 USA
关键词
CONTINUOUS VENOVENOUS HEMOFILTRATION; RENAL REPLACEMENT THERAPY; CARE-UNIT PATIENTS; VANCOMYCIN PHARMACOKINETICS; ADULT PATIENTS; ANTIMICROBIAL THERAPY; IN-VITRO; MEROPENEM; FAILURE; CIPROFLOXACIN;
D O I
10.1038/nrneph.2011.12
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
A common cause of acute kidney injury (AKI) is sepsis, which makes appropriate dosing of antibiotics in these patients essential. Drug dosing in critically ill patients with AKI, however, can be complicated. Critical illness and AKI can both substantially alter pharmacokinetic parameters as compared with healthy individuals or patients with end-stage renal disease. Furthermore, drug pharmacokinetic parameters are highly variable within the critically ill population. The volume of distribution of hydrophilic agents can increase as a result of fluid overload and decreased binding of the drug to serum proteins, and antibiotic loading doses must be adjusted upwards to account for these changes. Although renal elimination of drugs is decreased in patients with AKI, residual renal function in conjunction with renal replacement therapies (RRTs) result in enhanced drug clearance, and maintenance doses must reflect this situation. Antibiotic dosing decisions should be individualized to take into account patient-related, RRT-related, and drug-related factors. Efforts must also be made to optimize the attainment of antibiotic pharmacodynamic goals in this population. © 2011 Macmillan Publishers Limited. All rights reserved.
引用
收藏
页码:226 / 235
页数:10
相关论文
共 98 条
[1]   GENTAMICIN CLEARANCE DURING HEMODIALYSIS - A COMPARISON OF HIGH-EFFICIENCY CUPRAMMONIUM RAYON AND CONVENTIONAL CELLULOSE ESTER HEMODIALYZERS [J].
AGARWAL, R ;
TOTO, RD .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1993, 22 (02) :296-299
[2]  
AHERN JW, 2004, HOSP PHARM, V39, P138
[3]   Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore [J].
Ambrose, Paul G. ;
Bhavnani, Sujata M. ;
Rubino, Christopher M. ;
Louie, Arnold ;
Gumbo, Tawanda ;
Forrest, Alan ;
Drusano, George L. .
CLINICAL INFECTIOUS DISEASES, 2007, 44 (01) :79-86
[4]  
Aronoff G.R., 2007, Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, V5th
[5]   CLINICAL AND BACTERIOLOGICAL EFFICACY, AND PRACTICAL ASPECTS OF AMIKACIN GIVEN ONCE DAILY FOR SEVERE INFECTIONS [J].
BEAUCAIRE, G ;
LEROY, O ;
BEUSCART, C ;
KARP, P ;
CHIDIAC, C ;
CAILLAUX, M .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 27 :91-103
[6]   Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers [J].
Benvenuto, Mark ;
Benziger, David P. ;
Yankelev, Sara ;
Vigliani, Gloria .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (10) :3245-3249
[7]   Fluconazole dosing in continuous veno-venous haemofiltration (CVVHF): need for a high daily dose of 800 mg [J].
Bergner, R ;
Hoffmann, M ;
Riedel, KD ;
Mikus, G ;
Henrich, DM ;
Haefeli, WE ;
Uppenkamp, M ;
Walter-Sack, I .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (04) :1019-1023
[8]   Daptomycin Exposure and the Probability of Elevations in the Creatine Phosphokinase Level: Data from a Randomized Trial of Patients with Bacteremia and Endocarditis [J].
Bhavnani, Sujata M. ;
Rubino, Christopher M. ;
Ambrose, Paul G. ;
Drusano, George L. .
CLINICAL INFECTIOUS DISEASES, 2010, 50 (12) :1568-1574
[9]   VANCOMYCIN PHARMACOKINETICS IN NORMAL AND MORBIDLY OBESE SUBJECTS [J].
BLOUIN, RA ;
BAUER, LA ;
MILLER, DD ;
RECORD, KE ;
GRIFFEN, WO .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1982, 21 (04) :575-580
[10]   PHARMACOKINETICS AND SERUM BACTERICIDAL ACTIVITY OF VANCOMYCIN ALONE AND IN COMBINATION WITH CEFTAZIDIME IN HEALTHY-VOLUNTEERS [J].
BOECKH, M ;
LODE, H ;
BORNER, K ;
HOFFKEN, G ;
WAGNER, J ;
KOEPPE, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (01) :92-95